Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions
Amneal is pleased that recent FDA guidelines have contributed to lower biosimilar development costs • Source: Shutterstock 
